Product Description
INBRX-121 is a detuned, low-affinity IL-2 that is targeted to NKp46-expressing cells via two high-affinity single-domain antibodies (sdAb). (Sourced from: https://inhibrx.com/inbrx-121/#scroll)
Mechanisms of Action: IL2 Agonist
Novel Mechanism: Yes
Modality: Cytokine
Route of Administration: N/A
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Sanofi
Company Location: Europe
Company Founding Year: 1973
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 0: Oncology Solid Tumor Unspecified
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
03/24/2022 |
News Article |
Inhibrx Announces Details of Presentations at 2022 AACR Annual Meeting |
|
11/03/2021 |
News Article |
Inhibrx Announces Presentations at SITC 2021 |